Todos, NLC Meet Primary and Secondary Endpoints in Phase 2l Trial of Oral Covid Antiviral

 Phase 2 Study NLC-V-01 closed early after interim data analysis due to positive clinical efficacy

Primary endpoint of time to clinical improvement reached with average reduction of 2.7 days in the Tollovir group vs. the placebo group

 No COVID-related deaths in Tollovir™ group vs. 22% COVID-related deaths in placebo group

Lead clinical site Shaare Zedek Medical Center now permits the use of Tollovir™ in hospitalized COVID-19 patients on a compassionate use basis

Company preparing Phase 2/3 clinical trial to support Emergency Use Authorizations

Company to host conference call today at 9:15am ET to discuss the positive Phase 2 trial results

Company to make a corporate presentation for Emerging Growth Conference today at 3:00pm ET

https://www.globenewswire.com/news-release/2022/01/27/2374328/0/en/Todos-Medical-and-NLC-Pharma-Announce-Primary-and-Secondary-Endpoints-Met-in-NLC-V-01-Phase-2-Clinical-Trial-of-Oral-Antiviral-3CL-Protease-Inhibitor-Tollovir-in-the-Treatment-of-H.html